Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines.

The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.

Inclusion Criteria:

• Age > 18 years
• Diagnosis of exudative age-related macular degeneration requiring intravitreal anti-VEGF treatment.
• Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly more than 3 months
• Signature of informed consent
• Affiliation to the French social security system

Exclusion Criteria:

• Pregnant or nursing patient (a urinary pregnancy test will be performed)
• Systemic treatment with anti-VEGF
• Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated eye.
• Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis.
• Diabetes Mellitus
• High Myopia
• Simultaneous participation in another clinical research protocol in exudative AMD
• Person under guardianship, under curatorship, deprived of liberty